These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8389106)

  • 21. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The bioavailability and nonlinear pharmacokinetics of MK-679 in humans.
    Cheng H; Schwartz JI; Lin C; Amin RD; Seibold JR; Lasseter KC; Ebel DL; Tocco DJ; Rogers JD
    Biopharm Drug Dispos; 1994 Jul; 15(5):409-18. PubMed ID: 7981429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Lötvall J; Ankerst J
    Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function.
    Barnes N; Wei LX; Reiss TF; Leff JA; Shingo S; Yu C; Edelman JM
    Respir Med; 2001 May; 95(5):379-86. PubMed ID: 11392579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma.
    Wahedna I; Wisniewski AS; Tattersfield AE
    Br J Clin Pharmacol; 1991 Oct; 32(4):512-5. PubMed ID: 1958449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval.
    Bronsky EA; Kemp JP; Zhang J; Guerreiro D; Reiss TF
    Clin Pharmacol Ther; 1997 Nov; 62(5):556-61. PubMed ID: 9390112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults.
    Welch MJ; Nelson HS; Paull BR; Smith JA; Feiss G; Tobey RE
    Ann Allergy; 1994 Apr; 72(4):348-52. PubMed ID: 8154635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist.
    Margolskee DJ
    Ann N Y Acad Sci; 1991; 629():148-56. PubMed ID: 1659276
    [No Abstract]   [Full Text] [Related]  

  • 32. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels.
    Rodrigo G; Rodrigo C
    Am J Emerg Med; 1996 Mar; 14(2):144-50. PubMed ID: 8924135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
    Leff JA; Busse WW; Pearlman D; Bronsky EA; Kemp J; Hendeles L; Dockhorn R; Kundu S; Zhang J; Seidenberg BC; Reiss TF
    N Engl J Med; 1998 Jul; 339(3):147-52. PubMed ID: 9664090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of the endothelin-1 receptor antagonist, bosentan, on patients with poorly controlled asthma: a 17-week, double-blind, placebo-controlled crossover pilot study.
    Coyle TB; Metersky ML
    J Asthma; 2013 May; 50(4):433-7. PubMed ID: 23363065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
    Fogarty C; Hattersley H; Di Scala L; Drollmann A
    Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of LTD(4)in allergic pulmonary inflammation in mice: modulation by cysLT(1)antagonist MK-571.
    Blain JF; Sirois P
    Prostaglandins Leukot Essent Fatty Acids; 2000 Jun; 62(6):361-8. PubMed ID: 10913229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bronchodilator effect of Ipraterol on methacholine-induced bronchoconstriction in asthmatic patients.
    Maneechotesuwan K; Suthamsmai T; Ratanasaenglert K; Pipopsuthipaiboon S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S66-71. PubMed ID: 21728272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma.
    Rabe KF; Jörres R; Nowak D; Behr N; Magnussen H
    Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1436-41. PubMed ID: 8503554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.
    Bernstein JA; Liu N; Knorr BA; Smugar SS; Hanley WD; Reiss TF; Greenberg S
    Respir Med; 2011 Mar; 105(3):392-401. PubMed ID: 20970976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
    Beeh KM; Derom E; Kanniess F; Cameron R; Higgins M; van As A
    Eur Respir J; 2007 May; 29(5):871-8. PubMed ID: 17251236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.